PatientsVille.com Logo

PatientsVille

Kenacort Side Effects

Common Kenacort Side Effects


The most commonly reported Kenacort side effects (click to view or check a box to report):

Scleral Thinning (8)
Endophthalmitis (8)
Cytomegalovirus Chorioretinitis (8)
Retinal Artery Occlusion (7)
Retinal Detachment (6)
Glaucoma (5)
Adverse Event (5)
Anaphylactic Reaction (5)
Retinal Pigment Epitheliopathy (5)
Muscle Atrophy (5)
Intraocular Pressure Increased (5)
Atrophy (4)
Anaphylactic Shock (4)
Conjunctival Haemorrhage (4)
Anaphylactoid Reaction (4)
Injection Site Atrophy (4)
Paraesthesia (4)
Pain (4)
Haemarthrosis (4)
Necrotising Scleritis (3)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Kenacort Side Effects Reported to FDA

The following Kenacort reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Kenacort on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Petit Mal Epilepsy
This is a report of a 75-year-old female patient (weight: NA) from NL, suffering from the following symptoms/conditions: periarthritis,osteoporosis, who was treated with Kenacort-a40 Inj 40 Mg (dosage: NA, start time: Nov 11, 2005), combined with:
  • Teriparatide (1 Df=20 Mcg/ml Inj Fluid)
  • Depakine
  • Lidocaine
  • Phenobarbital Sodium
  • Ethosuximide
  • Calcichew (1 Df=500mg/400ie ?chewing Tablet)
  • Plaquenil Sulfate
  • Alendronic Acid
and developed a serious reaction and side effect(s). The consumer presented with:
  • Petit Mal Epilepsy
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Kenacort-a40 Inj 40 Mg treatment in female patients, resulting in petit mal epilepsy side effect.

Lipodystrophy Acquired, Injection Site Reaction
This report suggests a potential Kenacort Inj Lipodystrophy Acquired, Injection Site Reaction side effect(s) that can have serious consequences. A 57-year-old female patient (weight: NA) from FR was diagnosed with the following symptoms/conditions: NA and used Kenacort Inj (dosage: NA) starting 2012. Soon after starting Kenacort Inj the patient began experiencing various side effects, including:
  • Lipodystrophy Acquired
  • Injection Site Reaction
Drugs used concurrently: NA. Although Kenacort Inj demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as lipodystrophy acquired, may still occur.

Optic Neuritis
This Optic Neuritis problem was reported by a health professional from JP. A 50-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: macular oedema. On NS this consumer started treatment with Kenacort-a Inj (dosage: Intravitreal Injection). The following drugs were being taken at the same time: NA. When commencing Kenacort-a Inj, the patient experienced the following unwanted symptoms/side effects:
  • Optic Neuritis
The patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as optic neuritis, may become evident only after a product is in use by the general population.

Overdose, Cushing^s Syndrome
This is a report of a 37-year-old patient (weight: NA) from IT. The patient developed the following symptoms/conditions: NA and was treated with Kenacort (dosage: Formu:40mg/ml) starting NS. Concurrently used drugs: NA.Soon after that, the consumer experienced the following side effects:
  • Overdose
  • Cushing^s Syndrome
This opens a possibility that Kenacort treatment could cause the above reactions, including overdose, and some subjects may be more susceptible.


Hypoglycaemic Unconsciousness, Hypoglycaemia, Hyperglycaemia
A 43-year-old female patient (weight: NA) from NL with the following symptoms/conditions: arthralgia started Kenacort-a40 Inj treatment (dosage: Suspension 40mg/ml 1ml Flask) on 1978. Soon after starting Kenacort-a40 Inj treatment, the subject experienced various side effects, including:
  • Hypoglycaemic Unconsciousness
  • Hypoglycaemia
  • Hyperglycaemia
Concurrently used drugs:
  • Humalog (Injection Fluid 100e/ml 10ml Flask)
This finding indicates that some female patients could be more vulnerable to Kenacort-a40 Inj.

Csf Pressure Decreased, Headache, Paraesthesia
A 36-year-old male patient from IT (weight: NA) experienced symptoms, such as: NA and was treated with Kenacort Inj 40 Mg/ml(dosage: 1df=40 Mg/ml Inj Sol?1-unit/total). The treatment was initiated on Nov 11, 2013. After that a consumer reported the following side effect(s):
  • Csf Pressure Decreased
  • Headache
  • Paraesthesia
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Kenacort Inj 40 Mg/ml efficacy:
  • Lidocaine Hcl (1df=1-unit/total)
The patient was hospitalized.

Cushing^s Syndrome
In this report, Kenacort-a was administered for the following condition: NA.A 37-year-old female consumer from IT (weight: NA) started Kenacort-a treatment (dosage: NA) on NS.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Cushing^s Syndrome
A possible interaction with other drugs could have contributed to this reaction: NA.Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Kenacort-a treatment could be related to the listed above side effect(s).

Diverticulitis, Retinal Pigment Epitheliopathy, Systolic Hypertension
This is a report of the following Kenacort Inj side effect(s):
  • Diverticulitis
  • Retinal Pigment Epitheliopathy
  • Systolic Hypertension
A 49-year-old female patient from FR (weight: NA) presented with the following condition: nasal polyps,diverticulitis and received a treatment with Kenacort Inj (dosage: NA) starting: Sep 06, 2013.The following concurrently used drugs could have generated interactions:
  • Azactam For Inj 1 Gm (Last Dose: 19sep2013)
  • Metronidazole (Last Dose: 19sep2013)
The patient was hospitalized.This report suggests that a Kenacort Inj treatment could be associated with the listed above side effect(s).

Oesophageal Perforation
This Kenacort-a Inj report was submitted by a 55-year-old male consumer from JP (weight: NA). The patient was diagnosed with: anastomotic stenosis and Kenacort-a Inj was administered (dosage: NA) starting: NS. The consumer developed a set of symptoms:
  • Oesophageal Perforation
Other drugs used simultaneously: NA.Those unexpected symptoms could be linked to a Kenacort-a Inj treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Oesophageal Perforation
This is a report of a possible correlation between Kenacort-a Inj use and the following symptoms/side effect(s):
  • Oesophageal Perforation
which could contribute to an assessment of Kenacort-a Inj risk profile.A 67-year-old male consumer from JP (weight: NA) was suffering from anastomotic stenosis and was treated with Kenacort-a Inj (dosage: Kenacort-a Inj) starting NS.Other concurrent medications: NA.

Retinal Detachment
A 40-year-old male patient from JP (weight: NA) presented with the following symptoms: macular oedema,detachment of retinal pigment epithelium and after a treatment with Kenacort-a Inj (dosage: Subcapsular Injection) experienced the following side effect(s):
  • Retinal Detachment
The treatment was started on NS. Kenacort-a Inj was used in combination with the following drugs: NA.This report could alert potential Kenacort-a Inj consumers.

Oesophageal Perforation, Pneumomediastinum, Paraoesophageal Abscess
In this report, a 60-year-old male patient from JP (weight: NA) was affected by a possible Kenacort-a Inj 40 Mg/ml side effect.The patient was diagnosed with NA. After a treatment with Kenacort-a Inj 40 Mg/ml (dosage: 1ml:10mg Of 40mg/5ml,injected In To Submucosa, start date: NS), the patient experienced the following side effect(s):
  • Oesophageal Perforation
  • Pneumomediastinum
  • Paraoesophageal Abscess
The following simultaneously used drugs could have led to this reaction: NA.The patient was hospitalized.The findings here stress that side effects should be taken into consideration when evaluating a Kenacort-a Inj 40 Mg/ml treatment.

Nerve Injury, Neuralgia, Paralysis
This is a report of a 58-year-old male patient from NL (weight: NA), who used Kenacort (dosage: 21-aug-2013) for a treatment of sacroiliitis. After starting a treatment on Aug 21, 2013, the patient experienced the following side effect(s):
  • Nerve Injury
  • Neuralgia
  • Paralysis
The following drugs could possibly have interacted with the Kenacort treatment
  • Diclofenac Potassium Tabs 50 Mg
  • Paracetamol Tabs 500 Mg (1 Df: 2 Tabs)
Taken together, these observations suggest that a Kenacort treatment could be related to side effect(s), such as Nerve Injury, Neuralgia, Paralysis.

Cerebral Haemorrhage
This cerebral haemorrhage side effect was reported by a consumer or non-health professional from NL. A 77-year-old male patient (weight:NA) experienced the following symptoms/conditions: NA. The patient was prescribed Kenacort-a Inj 10 Mg/ml (dosage: NA), which was started on 2008. Concurrently used drugs:
  • Acenocoumarol
When starting to take Kenacort-a Inj 10 Mg/ml the consumer reported the following symptoms:
  • Cerebral Haemorrhage
The patient was hospitalized. These side effects may potentially be related to Kenacort-a Inj 10 Mg/ml.

Cubital Tunnel Syndrome
This is a Kenacort-a Inj side effect report of a 63-year-old male patient (weight:NA) from JP, suffering from the following symptoms/conditions: epicondylitis, who was treated with Kenacort-a Inj (dosage:NA, start time: NS), combined with: NA., and developed a serious reaction and a cubital tunnel syndrome side effect. The patient presented with:
  • Cubital Tunnel Syndrome
which developed after the beginning of treatment. This side effect report can indicate a possible existence of increased vulnerability to Kenacort-a Inj treatment in male patients suffering from epicondylitis, resulting in cubital tunnel syndrome.

Cubital Tunnel Syndrome
This report suggests a potential Kenacort-a Inj cubital tunnel syndrome side effect(s) that can have serious consequences. A 40-year-old male patient from JP (weight:NA) was diagnosed with the following health condition(s): epicondylitis and used Kenacort-a Inj (dosage: NA) starting NS. Soon after starting Kenacort-a Inj the patient began experiencing various side effects, including:
  • Cubital Tunnel Syndrome
Drugs used concurrently:NA. Although Kenacort-a Inj demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as cubital tunnel syndrome, may still occur.

Articular Calcification
This articular calcification problem was reported by a health professional from JP. A 51-year-old female patient (weight: NA) was diagnosed with the following medical condition(s): rheumatoid arthritis.On NS a consumer started treatment with Kenacort-a Inj (dosage: No Of Inj:22). The following drugs/medications were being taken at the same time:
  • Methotrexate
  • Abatacept
When commencing Kenacort-a Inj, the patient experienced the following unwanted symptoms /side effects:
  • Articular Calcification
Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as articular calcification, may become evident only after a product is in use by the general population.

Articular Calcification
This is a Kenacort-a Inj side effect report of a 58-year-old female patient (weight: NA) from JP. The patient developed the following symptoms/conditions: rheumatoid arthritis and was treated with Kenacort-a Inj (dosage: No Of Inj:22) starting NS. Concurrently used drugs:
  • Methotrexate
  • Infliximab
  • Prednisone
Soon after that, the consumer experienced the following of symptoms:
  • Articular Calcification
This opens a possibility that Kenacort-a Inj could cause articular calcification and that some female patients may be more susceptible.

Cytomegalovirus Chorioretinitis, Hypopyon
A 75-year-old male patient (weight: NA) from JP with the following symptoms: macular oedema started Kenacort-a Inj treatment (dosage: Intraocular(vitreous Injection) On 05sep07: 4mg?intraocular(sub-tennon) On 10sep07: 12mg) on Oct 11, 2007. Soon after starting Kenacort-a Inj treatment, the consumer experienced several side effects, including:
  • Cytomegalovirus Chorioretinitis
  • Hypopyon
. Concurrently used drugs:
  • Cravit
  • Diclod
  • Flumetholon
The patient was hospitalized. This finding indicates that some patients can be more vulnerable to developing Kenacort-a Inj side effects, such as cytomegalovirus chorioretinitis.

Tenosynovitis
This tenosynovitis side effect was reported by a consumer or non-health professional from JP. A 52-year-old male patient (weight:NA) experienced the following symptoms/conditions: NA.The patient was prescribed Kenacort Inj 10 Mg/ml (dosage: NA), which was started on NS. Concurrently used drugs: NA..When starting to take Kenacort Inj 10 Mg/ml the consumer reported symptoms, such as:
  • Tenosynovitis
These side effects may potentially be related to Kenacort Inj 10 Mg/ml.

Suppressed Lactation
This is a report of a 35-year-old female patient (weight: NA) from AU, suffering from the following symptoms/conditions: spinal pain, who was treated with Kenacort (dosage: 1df:80-120mg (total Dose). Injection., start time: NS), combined with: NA. and developed a serious reaction and side effect(s). The consumer presented with:
  • Suppressed Lactation
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Kenacort treatment in female patients, resulting in suppressed lactation side effect.

Injection Site Atrophy, Muscle Atrophy
This report suggests a potential Kenacort Retard 80 Inj Injection Site Atrophy, Muscle Atrophy side effect(s) that can have serious consequences. A 61-year-old female patient (weight: NA) from FR was diagnosed with the following symptoms/conditions: NA and used Kenacort Retard 80 Inj (dosage: NA) starting 201108. Soon after starting Kenacort Retard 80 Inj the patient began experiencing various side effects, including:
  • Injection Site Atrophy
  • Muscle Atrophy
Drugs used concurrently: NA. Although Kenacort Retard 80 Inj demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as injection site atrophy, may still occur.

Anaphylactic Shock, Urticaria, Gamma-glutamyltransferase Decreased
This Anaphylactic Shock, Urticaria, Gamma-glutamyltransferase Decreased problem was reported by a consumer or non-health professional from JP. A 70-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: trigger finger. On Jan 15, 2011 this consumer started treatment with Kenacort (dosage: Route:intra Tendon Inj). The following drugs were being taken at the same time:
  • Xylocaine (Route:intra Tendon Inj)
  • Ursodeoxycholic Acid (Tab)
  • Atenolol Tabs
  • Unisia (1df=8mg + 5mg)
  • Crestor (Tab)
When commencing Kenacort, the patient experienced the following unwanted symptoms/side effects:
  • Anaphylactic Shock
  • Urticaria
  • Gamma-glutamyltransferase Decreased
The patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as anaphylactic shock, may become evident only after a product is in use by the general population.

Blood Cortisol Decreased, Diabetes Mellitus, Hypertension, Hyperglycaemia, Cushingoid, Cushing's Syndrome
This is a report of a 39-year-old female patient (weight: NA) from SWITZERLAND. The patient developed the following symptoms/conditions: back pain,osteoporosis,hiv infection and was treated with Kenacort-a Ophthalmic Ointment (dosage: One Single Administration) starting Jan 01, 2011. Concurrently used drugs:
  • Calcimagon-d3
  • Norvir
  • Prezista
  • Truvada
  • Rasilez
Soon after that, the consumer experienced the following side effects:
  • Blood Cortisol Decreased
  • Diabetes Mellitus
  • Hypertension
  • Hyperglycaemia
  • Cushingoid
  • Cushing's Syndrome
This opens a possibility that Kenacort-a Ophthalmic Ointment treatment could cause the above reactions, including blood cortisol decreased, and some female subjects may be more susceptible.

Retinal Artery Occlusion, Anaphylactoid Reaction
A 51-year-old female patient (weight: NA) from JAPAN with the following symptoms/conditions: sinusitis started Kenacort treatment (dosage: 1df= 40 Mg/1 Ml) on Nov 24, 2011. Soon after starting Kenacort treatment, the subject experienced various side effects, including:
  • Retinal Artery Occlusion
  • Anaphylactoid Reaction
Concurrently used drugs: NA.The patient was hospitalized. This finding indicates that some female patients could be more vulnerable to Kenacort.

1 of 8 



Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Kenacort Side Effects

    Did You Have a Kenacort Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Kenacort for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective